Retatrutide's Phase 2 TRIUMPH-1 trial (N Engl J Med 2023) tracked adverse events across 338 participants on 1, 4, 8, and 12 mg doses versus placebo over 48 weeks. This page summarizes what was reported, how common each effect was, and how it compares to related GLP-1/GIP drugs.
Common retatrutide side effects (dose-dependent, GI-dominant)
| Side effect | 1 mg arm | 4 mg arm | 8 mg arm | 12 mg arm | Placebo |
|---|---|---|---|---|---|
| Nausea | 30% | 38% | 46% | 55% | 9% |
| Diarrhea | 18% | 25% | 29% | 32% | 8% |
| Vomiting | 7% | 11% | 16% | 21% | 2% |
| Constipation | 12% | 14% | 13% | 16% | 6% |
| Fatigue | 7% | 10% | 12% | 15% | 4% |
| Decreased appetite | 30% | 45% | 55% | 60% | 6% |
| Injection-site reaction | 6% | 6% | 7% | 8% | 3% |
Percentages approximated from published supplementary data. See NEJM 2023 for exact figures.
The key pattern: nausea, diarrhea, vomiting, and constipation are dose-dependent and concentrated in the first weeks of each dose escalation. They are almost never continuous — they spike with an escalation, moderate within 2–4 weeks, and return to a low baseline until the next step up. This is why slow titration matters.
Retatrutide nausea
The dominant side effect. Most commonly reported during the first week on a new dose rung. Strategies that reduce incidence: smaller and more frequent meals, avoiding high-fat meals immediately post-injection, ginger, and simply slowing the titration schedule (holding each rung for 6 weeks instead of 4).
Retatrutide diarrhea
Often paired with nausea in the first 1–2 weeks post-escalation. Hydration is critical — a slowed-digestion stomach loses fluids quickly if diarrhea compounds. Electrolyte replacement and temporarily low-residue diet (bland carbs, bananas, rice) help.
Retatrutide constipation
The flip side of slowed gastric emptying. More common on stable maintenance doses. Fiber (psyllium), adequate water, and occasional osmotic laxatives (Miralax) are usually enough.
Retatrutide fatigue
Moderate fatigue is common during weight loss at any rate, and retatrutide amplifies it via caloric restriction. Adequate protein (1.2–1.6 g/kg lean mass/day), iron and B12 status check, and consistent sleep make a measurable difference.
Less common side effects
Retatrutide hair loss
Reported in ~5–10% of participants on 8–12 mg. Current interpretation: telogen effluvium secondary to rapid weight loss and caloric restriction — the same pattern seen with tirzepatide and semaglutide at comparable weight-loss rates. Typically reverses 3–6 months after weight stabilization. Mitigation: adequate protein, iron, biotin, zinc, and vitamin D.
Retatrutide muscle loss
DEXA data from TRIUMPH-1 substudy showed ~82% of weight lost was fat mass, but ~18% was lean tissue. This is standard for aggressive weight loss. Reduction strategies: 1.2–1.6 g protein per kg lean body mass daily, resistance training 2–3×/week, and — if weight loss is faster than ~1% per week — deliberately slowing it.
Retatrutide skin sensitivity
A small fraction of participants reported increased skin sensitivity, usually around injection sites. True drug hypersensitivity is rare; most reports reflect local injection-site reactions that resolve with site rotation and correct injection technique.
Heart rate and blood pressure
Mean resting heart rate rose 3–8 bpm across dose arms — a class-wide GLP-1 effect. Blood pressure decreased meaningfully: systolic ~8 mmHg on 12 mg. The net cardiovascular picture in Phase 2 was favorable, though TRIUMPH-3 is the dedicated cardiovascular-outcomes trial.
Blood sugar effects
A small transient hyperglycemia signal appeared at the 12 mg dose in non-diabetic participants — consistent with the glucagon-receptor component pushing glucose slightly up before the GLP-1/GIP compensation catches up. Managed by dose titration. In the T2D population (TRIUMPH-2), the net effect was strongly glucose-lowering (A1C down 2.0 points on 12 mg).
Rare and serious adverse events
- Pancreatitis — GLP-1 class risk. No excess over placebo in TRIUMPH-1, but the absolute event count was small given trial size.
- Gallbladder events (cholelithiasis) — weight-loss-associated. Incidence tracks with the magnitude of weight loss, not the specific drug.
- Medullary thyroid carcinoma / MEN2 — class-wide contraindication. No human signal but rodent studies produced C-cell tumors at supra-therapeutic doses. Retatrutide will carry the same boxed warning as tirzepatide and semaglutide if approved.
- Severe hypoglycemia — not observed in non-diabetics. In T2D participants on insulin or sulfonylureas, adjustment of background therapy is required.
Retatrutide side effects vs tirzepatide and semaglutide
Cross-trial comparison (different populations, durations, escalation speeds) suggests retatrutide's GI side effect rate is moderately higher than semaglutide and roughly comparable to tirzepatide at dose levels that produce similar weight loss. The glucagon component doesn't appear to add meaningful GI burden on top of GLP-1/GIP.
| Side effect | Retatrutide (12 mg) | Tirzepatide (15 mg) | Semaglutide (2.4 mg) |
|---|---|---|---|
| Nausea | 55% | 45% | 40% |
| Diarrhea | 32% | 25% | 30% |
| Vomiting | 21% | 15% | 20% |
| Constipation | 16% | 17% | 25% |
| Weight loss (avg) | 24.2% (48w) | 22.5% (72w) | 14.9% (68w) |
Drug interactions
Formal drug-interaction studies are incomplete (Phase 3 ongoing), but based on mechanism and class:
- Oral medications: slowed gastric emptying can delay absorption. Time-sensitive medications (oral contraceptives, antibiotics, anticoagulants) should be reviewed with a prescriber.
- Insulin / sulfonylureas: risk of hypoglycemia in diabetics; background therapy must be reduced.
- Alcohol: no absolute contraindication but compounds dehydration and blood-sugar variability.
- Other GLP-1 agonists: do not combine. Retatrutide already activates the GLP-1 receptor maximally; adding semaglutide or tirzepatide adds side effects without added benefit.
- Cagrilintide: amylin analog, occasionally combined in peptide-community protocols. Safety of the combination is not established.
What to do about side effects
- Slow down. Most side effects are dose-escalation artifacts. Holding your current dose for an additional 2–4 weeks before escalating eliminates most problems.
- Hydrate. GI symptoms drop measurably with 2.5–3 L water daily plus electrolytes.
- Protein first. Muscle loss and hair loss both correlate with inadequate protein. 1.2–1.6 g/kg lean mass/day.
- Smaller, lower-fat meals. Nausea is worst after large or high-fat meals.
- Consistency. Same injection day, same site rotation, same routine — weight-loss rate and side-effect rate both stabilize.
- Talk to a doctor if symptoms are severe. Uncontrolled vomiting, severe abdominal pain, signs of dehydration warrant evaluation. The supervised alternative — prescription GLP-1 — includes this by default.